NCT00750633
Completed
Phase 3
A Phase III Study of an Otic Formulation in Acute Otitis Externa
ConditionsAcute Otitis Externa
Overview
- Phase
- Phase 3
- Intervention
- Moxidex otic solution
- Conditions
- Acute Otitis Externa
- Sponsor
- Alcon Research
- Enrollment
- 990
- Primary Endpoint
- Clinical Cure
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to determine if an otic formulation is safe and effective for the treatment of acute otitis externa (AOE).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of AOE based on clinical observation and of presumed bacterial origin
- •A minimum combined score of ≥4 in at least 1 affected ear at the Day 1 exam for tenderness, erythema, and edema
- •Other protocol-defined inclusion criteria may apply
Exclusion Criteria
- •Duration of pretherapy signs or symptoms of AOE greater than four (4) weeks
- •Presence of a tympanostomy tube or perforated tympanic membrane in the treated ear(s). Patients with a history of tympanic membrane perforation should not be enrolled unless the absence of a current perforation can be confirmed at Visit 1 prior to enrollment
- •Clinically diagnosed chronic suppurative otitis media, acute otitis media, acute otorrhea in patients with tympanostomy tubes, or malignant otitis externa
- •Known or suspected ear infection of fungal or mycobacterial origin
- •Prior otologic surgery within 6 months of study entry
- •Seborrheic dermatitis or other skin conditions of the external auditory canal
- •Current or prior history of an immunosuppressive disorder (e.g., HIV positive) or current immunosuppressive therapy (e.g., cancer chemotherapy) or known acute or chronic renal disorders or active hepatitis
- •Diabetic patients (controlled or uncontrolled) based upon assessment by Investigator
- •Any systemic disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study \[e.g., cleft palate (including repairs), Downs Syndrome, and cranial facial reconstruction\]
- •Any current known or suspected infection (other than AOE) requiring systemic antimicrobial therapy
Arms & Interventions
Moxidex
Moxidex otic solution
Intervention: Moxidex otic solution
Moxidex
Moxidex otic solution
Intervention: Tympanostomy tubes
Moxifloxacin
Moxifloxacin otic solution
Intervention: Moxifloxacin otic solution
Moxifloxacin
Moxifloxacin otic solution
Intervention: Tympanostomy tubes
Dexamethasone
Dexamethasone phosphate otic solution
Intervention: Dexamethasone phosphate otic solution
Dexamethasone
Dexamethasone phosphate otic solution
Intervention: Tympanostomy tubes
Outcomes
Primary Outcomes
Clinical Cure
Time Frame: Day 12
Secondary Outcomes
- Microbiological Success(Day 12)
Similar Trials
Completed
Phase 2
A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube OtorrheaAcute Otitis MediaNCT00578773Alcon Research303
Completed
Phase 3
A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy TubesAcute Otitis MediaNCT00578474Alcon Research911
Completed
Phase 3
Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy TubesAcute Otitis MediaNCT00579189Alcon Research776
Terminated
Phase 1
A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)Chronic Tympanic Membrane PerforationNCT04305184Astellas Pharma Global Development, Inc.36
Completed
Not Applicable
EarGenie: Assessment of a Minimum Viable ProductHearing Impaired ChildrenNCT05962814The Bionics Institute of Australia11